Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.
Zhu, Feng-Cai; Chen, Wen; Hu, Yue-Mei; Hong, Ying; Li, Juan; Zhang, Xun; Zhang, Yi-Ju; Pan, Qin-Jing; Zhao, Fang-Hui; Yu, Jia-Xi; Zhang, Yan-Shu; Yang, Xiaoping; Zhang, Cheng-Fu; Tang, Haiwen; Zhang, Helen; Lebacq, Marie; David, Marie-Pierre; Datta, Sanjoy K; Struyf, Frank; Bi, Dan; Descamps, Dominique.
Int J Cancer
; 135(11): 2612-22, 2014 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-24740596
Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland.
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
High prevalence of genital HPV infection among long-term monogamous partners of women with cervical dysplasia or genital warts-Another reason for HPV vaccination of boys.
Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis.
Secondary prevention of cervical cancer part 3: evidence-based management of women with cervical intraepithelial neoplasia.
Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial.
Colposcopy and cytodiagnosis in the prevention of cervical malignancies.
Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study.
HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico.
Prospective study of hTERC gene detection by fluorescence in situ hybridization (FISH) in cervical intraepithelial neoplasia 1 natural prognosis.